Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

NCT07369986 | Not Yet Recruiting Phase 2

• 1 other identifier: PRO2025-811
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.

Conditions

Endometrial Cancer; Immunotherapy; Mismatch Repair Deficiency

Outcome Measures

Primary Outcomes (1)

• Pathological or clinical complete response rate

  From the time of enrollment until 12 months after the completion of treatment

Study Arms (1)

Immunotherapy

EXPERIMENTAL

Drug: Iparomlimab and Tuvonralimab (QL1706)

Interventions

Iparomlimab and Tuvonralimab (QL1706) DRUG

Iparomlimab and Tuvonralimab as a strategy to facilitate non-surgical management in women with surgically completely resectable dMMR endometrial cancer.

Immunotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age:18 years or older.
• Histologically confirmed endometrial cancer (excluding carcinosarcoma).
• FIGO (2009) stage I to IIIC2 disease that is considered surgically completely resectable.
• Confirmed dMMR or MSI-H, defined by either loss of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6 or MSI-H) for by immunohistochemistry, or MSI-H status confirmed by polymerase chain reaction assay.
• )No prior systemic anti-tumor therapy (including chemotherapy, radiotherapy, targeted therapy, or immunotherapy) within the past 5 years.
• )Eastern Cooperative Oncology Group Performance Status of 0 or 1. 7)Laboratory test results within 7 days prior to the first dose must meet the following criteria. Laboratory values are not valid if the patient received granulocyte colony-stimulating factor or a blood transfusion within 14 days prior to sample collection.
• White blood cell count ≥2,000/mm3 and absolute neutrophil count ≥1,500/mm3. Platelet count ≥100,000/mm3. Hemoglobin ≥9.0 g/dL.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0-fold of the upper limit of normal (ULN) (or ≤5.0-fold the ULN of the study site in patients with liver metastases). Total bilirubin ≤1.5-fold of the ULN.
• Creatinine ≤1.5-fold of the ULN or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) ≥ 45 mL/min.
• )Women of childbearing potential:
• Must agree to use contraception from the time of informed consent until at least 5 months after the last dose of the investigational product.
• Must agree not to breastfeed from the time of informed consent until at least 5 months after the last dose.

You may not qualify if:

• )Multiple primary malignancies, except for: adequately resected basal cell or squamous cell carcinoma of the skin (Stage I), superficial bladder cancer, or any other malignancy that has been disease-free for over 5 years.
• History of severe hypersensitivity to any monoclonal antibody. 3)Known hypersensitivity to iparomlimab and tuvonralimab or any of their excipients.
• )Concurrent or history of clinically significant autoimmune disease. 5)Current or prior interstitial lung disease or pulmonary fibrosis documented by imaging or clinical assessment. Patients with radiation pneumonitis may be enrolled if it is confirmed to be stable (beyond the acute phase) and without anticipated recurrence.
• )Concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease. 7)Symptomatic pericardial effusion, pleural effusion, or ascites requiring treatment.
• )Uncontrolled tumor-related pain. 9)Transient ischemic attack, cerebrovascular accident, or thromboembolism within 180 days prior to enrollment.
• )Uncontrolled or clinically significant cardiovascular disease, defined as any of the following within 180 days prior to enrollment:
• Myocardial infarction;
• Unstable angina pectoris;
• Congestive heart failure of New York Heart Association (NYHA) Class III or IV
• Poorly controlled hypertension despite appropriate treatment (e.g., sustained systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg for ≥ 24 hours)
• Arrhythmia requiring treatment 11)Requirement for ongoing therapeutic anticoagulation (low-dose aspirin or other antiplatelet therapy is permitted).
• )Poorly controlled diabetes mellitus. 13)Active systemic infection requiring treatment. Systemic corticosteroid therapy (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before enrollment.
• )Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular targeted therapy agents, or immunotherapy agents) within 28 days before randomization.
• )Administration of any therapeutic radiopharmaceutical within 56 days prior to enrollment (diagnostic use is permitted).
• )Active tuberculosis. 20)Positive serology for human immunodeficiency virus (HIV-1/2 antibody), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. Patients who are HBsAg-positive may be enrolled if hepatitis B virus DNA is below the lower limit of detection.

Sponsors & Collaborators

• Women's Hospital School Of Medicine Zhejiang University: lead

MeSH Terms

Conditions

Endometrial Neoplasms; Turcot syndrome

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Central Study Contacts

Yang Li

CONTACT

+86-571-87061501; li_yang@zju.edu.cn

Xiaojie Wan

CONTACT

86-13957756553; 5518006@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 18, 2026
• First Posted: January 27, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: January 27, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share